Nehal N. Mehta, MD, MSCE

Emailnehal.mehta@nih.gov

Faculty Information

CCEB AppointmentAdjunct Scholar, Epidemiology
Non-Penn AppointmentChief, Section of Inflammation and Cardiometabolic Diseases
National Heart, Lung and Blood Institute

Research Statement

Dr. Nehal N. Mehta received his MSCE with a focus in genetic epidemiology. He is currently the Director of the Inflammatory Risk Clinic within Preventive Cardiology. He has clinical and research interests in moving epidemiological observations into translational studies in humans studying how inflammation affects insulin resistance, the metabolic syndrome, lipoprotein function and atherosclerosis. He is also trained in Nuclear Cardiology and utilizes novel imaging techniques to understand the effect of various exposures on atherosclerotic plaque activity and vascular inflammation. Collaborating with Dr. Joel M. Gelfand, MD, MSCE, he is currently focused on cardiovascular risk stratification of patients with psoriasis, and understanding the mechanisms of the skin/vascular disease link using psoriasis as a model of study the effect of in vivo inflammation on vascular inflammation using FDG PET/CT. His long term goal is to improve risk stratification and risk prediction for heart disease in novel populations, and apply imaging sciences to refine effects of therapeutics and genomics on vascular disease. He is the recipient of an NIH career-development award which examines the role of an inflammatory chemokine in a population-based study, then studying the chemokine in cells and tissues involved in atherosclerosis to dissect mechanism of disease. This project is under the mentored guidance of Drs. Muredach P. Reilly MBBCh, MSCE and Daniel J. Rader, MD. Dr. Mehta is board certified in internal medicine, nuclear cardiology, echocardiography and cardiovascular diseases.

Selected Publications

Reilly MP, Wolfe M, Rhodes T, Girman C, Mehta NN, Rader DJ. The Metabolic Syndrome and Coronary Atherosclerosis: Measures of Insulin Resistance Add Incremental Value to the NCEP Metabolic Syndrome Criteria in the Association with Coronary Artery Calcification. Circulation 2004; 110(7):803-809.

Mehta, NN and Reilly, MP. : Assessment of Cardiovascular Risk in the HAART-Treated HIV-1 Population. HIV Clinical Trials 2005; 6(1):5-24.

Anderson, PD, Mehta, NN, Wolfe, ML, Hinkle, CC, Pruscino, L, Comiskey, LL, Tabita-Martinez, J, Sellers, KF, Rickels, MR, Ahima, RS, Reilly, MP: Innate immunity modulates adipokines in humans. Journal Of Clinical Endocrinology And Metabolism 2007; 92(6): 2272-2279.

Qasim, A, Mehta, NN, Tadesse, MG, Wolfe, ML, Rhodes, T, Girman, C, Reilly, MP: Adipokines, insulin resistance, and coronary artery calcification. Journal Of The American College Of Cardiology 2008; 52(3):231-236.

Mehta, NN, Sheetz, M, Price, K, Comiskey, L, Amrutia, S, Iqbal, N, Mohler, ER, Reilly, MP: Selective PKC Beta Inhibition with Ruboxistaurin and Endothelial Function in Type-2 Diabetes Mellitus. Cardiovascular Drugs And Therapy 2009; 23(1):17-24.

Martin SS, Qasim AN, Mehta NN, Wolfe M, Terembula K, Schwartz S, Iqbal N, Schutta M, Bagheri R, Reilly MP. Apolipoprotein B but not LDL cholesterol is associated with coronary artery calcification in type 2 diabetic whites. Diabetes 2009; 58(8), 1887-92. PMC2712798.

Shah R, Lu Y, Hinkle CC, McGillicuddy FC, Kim R, Hannenhalli S, Cappola TP, Heffron S, Wang X, Mehta NN, Putt M, Reilly MP. (2009). Gene profiling of human adipose tissue during evoked inflammation in vivo. Diabetes 2009; 58(10), 2211-9. PMC2750231.

Mehta NN, McGillicuddy FC, Anderson PD, Hinkle CC, Shah R, Pruscino L, Tabita-Martinez J, Sellers KF, Rickels MR, Reilly MP. Experimental Endotoxemia Induces Adipose Inflammation and Insulin Resistance in Humans. Diabetes 2010; 59(1):172-81.

Mehta NN, Azfar, RS, Shin, DB, Neimann, AL, Troxel, AB, and Gelfand, JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: A cohort study using the General Practice Research Database. European Heart Journal 2010;31:1000-6

Gelfand JM, Azfar RS, Mehta NN. (2010) Psoriasis and Cardiovascular Risk: Strength in Numbers. Journal of Investigational Dermatology. April;130(4):919-22.

Reilly MP, Li M, Ferguson JF, Stylianou IM, Mehta NN et al. (2011). Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome wide association studies. Lancet (in press Jan 2011).

Mehta NN, Krishnamoorthy P, Martin SS, Braunstein S, Iqbal N, Schwartz S, Schutta M, Rader DJ, Reilly MP. Insulin Resistance Estimation and the Metabolic Syndrome in Predicting Coronary Atherosclerosis in Type 2 Diabetes Mellitus. American Journal of Cardiology (in press Feb 2011).

Mehta NN, William D, Khera A, Edmondson A, Qasim A, Restine S, Pruscino L, Hinkle C, He J, Stylianou I, Li M, Rader DJ, Reilly MP (2011). A Novel GWAS Atherosclerosis Locus Regulates Plasma Levels of CXCL12. European Heart Journal (in press March 21st, 2011).

Gelfand JM, Mehta NN, Langan S. (2011) Psoriasis and Cardiovascular Risk Part II: Strength in Numbers. Journal of Investigational Dermatology. (in press March 18th, 2011)

Mehta NN, Yu Y, Shin DB, Pinnelas R, Krishnamoorthy P, Troxel A, Gelfand J. Estimation of the Attributable Risk of Psoriasis on Major Cardiac Events. American Journal of Medicine (in press Aug 2011).

Mehta, NN, Yu Y, Saboury B, Foroughi N, Krishnamoorthy P, VanVoorhees A, Alavi A, Gelfand J. Systemic and Vascular Inflammation in Patients with Moderate to Severe Psoriasis as measured by [18F]-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET): A Pilot Study. Archives of Dermatology (in press Aug 2011).



Penn Medicine CCEB Home